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Abstract Poloxamer 188 (P188) is a non-ionic amphi-
philic copolymer with hemorheologic, antithrombotic, anti-
inflammatory, and cytoprotective properties. It potentially
has clinical utility in diverse diseases, such as acute myo-
cardial infarction, acute limb ischemia, shock, acute stroke,
heart failure, and sickle cell crisis. P188 is available as an
excipient-grade product, manufactured to National For-
mulary specifications, which we refer to as P188-NF.
During synthesis of P188-NF, polymerization of its poly-
oxyethylene and polyoxypropylene components generates
undesirable low molecular weight (LMW) substances, such
as truncated polymers and glycols. In early clinical studies,
P188-NF yielded unexpected renal dysfunction. Here, we
explore the nature of the renal dysfunction associated with
P188-NF and use a purified (more homogenous) form of
P188-NF (P188-P) to show that removal of LMW sub-
stances is associated with substantially less renal dys-
function. In both a remnant-kidney animal model and in
clinical studies, P188-P demonstrates a substantially
improved renal safety profile.
1 Introduction
Poloxamer 188 (P188) is a non-ionic amphiphilic copoly-
mer consisting of a central chain of hydrophobic poly-
oxypropylene flanked at both ends by hydrophilic
polyoxyethylene. The average molecular weight is about
8,500 kD (Fig. 1). The term ‘‘poloxamer’’ generically
applies to the different triblock copolymers made by
varying the lengths of the polyoxypropylene and poly-
oxyethylene blocks. The copolymers are commonly named
with the letter ‘‘P’’ (for poloxamer) followed by three
digits, the first two digits 9 300 give the approximate
molecular mass of the polyoxypropylene core, and the last
digit 9 10 gives the percentage polyoxyethylene content
(e.g., P188 indicates a polyoxypropylene molecular mass
of 5,400 g/mol and 80 % polyoxyethylene content).
P188 binds to damaged cell membranes in areas of
decreased lipid density, promoting stability and restoring
membrane barrier function [1, 2]. In addition to these direct
effects on membrane integrity, P188 has been shown to
almost completely prevent lipid peroxidation induced by
Fe2? and H2O2 [3]. P188 binding serves to maintain the
asymmetric distribution of phospholipids within cell
membranes, preventing the ‘‘flip-flopping’’ and surface
exposure of phosphatidylserine, without which the initia-
tion of coagulation or the recognition process leading to the
clearance of apoptotic cells is blocked [4]. Stopping
transmembrane phospholipid redistribution is also known
to hinder red blood cell transformation to echinocytes (i.e.,
echinocytosis) and release of membrane microparticles
(i.e., microvesiculation) [5]. Membrane-bound P188 also
reduces surface tension and hydrophobic-based cellular
adherence, which can hinder the free movement of blood
cells within the vasculature and initiate thrombotic and
inflammatory cascades [6, 7]. Video microscopy demon-
strates that P188 improves the elastic properties of red
blood cells, improving their deformability and increasing
their ability to pass through small channels often smaller
than the red blood cell diameter [8]. Its biophysical prop-
erties also account for its widespread use as a surfactant in
the preparation of nanoparticles and micelles to transduce
various payloads into cells [9, 10].
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An accumulating number of studies suggest that P188
has potential clinical utility, particularly in conditions
characterized by poor microvascular blood flow or where
cellular function may be compromised by a damaged cell
membrane [11–14]. P188 exhibits clinically desirable he-
morheologic properties, reducing blood viscosity [15, 16]
and red blood cell aggregation [17, 18]. When used in
combination with tissue plasminogen activator or strepto-
kinase, it markedly increases fibrinolysis [19, 20]. In
models of acute myocardial infarction (AMI), P188
reduced the infarct size by 40–50 % and improved the left
ventricular ejection fraction by about 30 % [21, 22].
Although it is not an anticoagulant, P188 has been shown
to diminish thrombotic coronary occlusion after arterial
injury and stent placement in a porcine model [23]. It
induced normal perfusion (Thrombolysis in Myocardial
Infarction [TIMI] grade 3 flow) following primary percu-
taneous transluminal coronary angioplasty following acute
myocardial infarction [24]. In models of experimental
shock, P188 significantly improved the median survival
time in miniature swine after severe controlled hemor-
rhage, compared with that observed in controls
(p = 0.0186) [25]. Zhang et al. [26] evaluated P188 in
multiple rat models of hemorrhagic shock. In these studies,
P188 improved survival (p \ 0.001), as well as signifi-
cantly decreasing the fluid requirements required to regain
and maintain hemodynamic performance goals
(p = 0.0002) and reducing tissue permeability/fluid
extravasation in the lung and small intestine (p \ 0.01),
while maintaining core organ perfusion and reducing
markers of inflammation and apoptosis. In other animal
models of ischemia/reperfusion injury, P188 preserved the
integrity of neuronal cell membranes, as well as the
integrity of the blood–brain barrier. Control mice subjected
to transient focal ischemia showed numerous propidium
iodide (PI)-labeled cells in ischemic areas, including the
hippocampus and striatum, but no PI-positive cells were
detected in the contralateral hemisphere. P188 treatment
significantly reduced the PI-positive cells in the hippo-
campus and striatum area [27]. More recently, phase 2 and
3 studies in patients with sickle cell crisis have shown that
treatment with P188 is associated with a reduction in the
duration of crisis [28, 29].
P188 is available as an excipient-grade product, manu-
factured to National Formulary specifications, which we
refer to as P188-NF. Early clinical studies of P188, per-
formed prior to 1996, were conducted using P188-NF. Initial
studies in patients with sickle cell disease (SCD) and AMI
were promising and demonstrated important clinical benefits
[28, 30]. However, in larger studies in patients with AMI,
P188-NF was associated with dose-dependent, moderate to
moderately severe elevations in serum creatinine levels.
These changes were most obvious in subjects aged 65 years
and greater and in those with elevated creatinine levels at
baseline [31]. Development of P188-NF was discontinued
following this finding. P188 is chemically synthesized in two
steps, first by building the (poly)oxypropylene core, and
second by addition of poly(oxyethylene) to the terminal ends
of the polyoxypropylene core. Because of variation in the
rates of polymerization during both steps, P188-NF consists
of a bell-shaped distribution of polymer species, which vary
primarily in overall chain length. In addition, various low
molecular weight (LMW) substances (e.g., glycols and
truncated polymers), formed by incomplete polymerization,
and dimerized polymers typically are present. Character-
ization of P188-NF using gel permeation chromatography
(GPC) identifies a main peak of P188 with ‘‘shoulder’’ peaks
on both sides representing the unintended LMW and high
molecular weight (HMW) related substances. We hypothe-
sized that the LMW substances present in P188-NF were
causal and/or contributed disproportionately to the renal
dysfunction observed with this agent. We further hypothe-
sized that removal of these substances would result in an
agent with substantially less effect on renal function, without
otherwise affecting its activity. Here, we show the nature of
the renal injury associated with P188-NF and demonstrate
that a ‘‘purified’’ and less polydisperse form of P188, which
we refer to as P188-P1 throughout this publication, has a
significantly lesser effect on renal function in a remnant-
kidney animal model and is well tolerated in clinical studies.
The role of the unpurified, excipient-grade material (P188-
NF), and its impact on the results obtained in earlier clinical
trials, is also discussed.
2 Materials and Methods
2.1 Purification of P188-NF
A supercritical fluid extraction process was used to prepare
P188-P. Commercial-grade poloxamer 188 (P188-NF;
BASF Corporation) was supported on a polystyrene divinyl
1 The nomenclature associated with P188-P has changed over the
years. It is currently referred to as MST-188, but previously has been
called CRL 5861 and FLOCOR.
Fig. 1 Chemical formula for poloxamer 188 (P188). With n = 80
and m = 27, P188 has a calculated molecular weight of 8,624 kD
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benzene solid matrix (XAD-4; Supelco) in a high-pressure
stainless steel vessel and extracted with carbon dioxide and
modifying co-solvents (approximately 4 mole %) at
6,000 psi and 40 C. The extraction proceeded until
approximately 80 % of the total LMW material had been
removed as analyzed by GPC. When the extraction was
complete, methanol was used to elute the purified polox-
amer 188 (P188-P) from the matrix. The waste stream was
also collected and evaporated. The yield of P188-P was
typically 75–80 % of the loaded P188-NF. Gas chroma-
tography and nuclear magnetic resonance were used to
analyze the levels of unsaturation groups and LMW glycol
species in P188-NF and P188-P, respectively. A similar
supercritical fluid extraction process modified to comply
with Current Good Manufacturing Practice (cGMP) was
used to prepare P188-P for clinical studies. Clinical-grade
P188-P was sterilized via a terminal autoclaving process,
which had been pre-validated by measuring the recovery of
reference material post-treatment.
2.2 Test Agents
For all studies, both P188-NF and P188-P were formulated
as a 15 % sterile aqueous solution of the appropriate agent
in a vehicle containing sodium chloride 3.08 mg/mL,
sodium citrate 2.38 mg/mL, and citric acid 0.366 mg/mL.
Control infusions were conducted using only the vehicle.
2.3 Remnant-Kidney Animal Model
Female Sprague–Dawley rats, aged 6–8 weeks, were sub-
jected to 5/6 nephrectomy, as described by Anderson et al.
[32–34], and were allowed to recover for at least 15 days.
Remnant-kidney rats with stable renal function were
stratified by renal function and randomized to treatment
groups. The treatment-group animals were anesthetized
(using an intraperitoneal injection of ketamine 15–20 mg/
kg) and intravenously infused for 6 h via the tail vein with
supra-pharmacologic dosages of P188-P or P188-NF, using
a syringe infusion pump (Harvard Apparatus). Three con-
trol animals similarly received a 6 h infusion of vehicle
only. The infusion rates were 0.3–0.4, 0.6–0.8, and
1.2–1.6 mL/h in the 250, 500, and 1,000 mg/kg dose
groups, respectively. The number of animals in each
treatment group was as follows: 4, 6, and 25 animals
received P188-P in the 250, 500, and 1,000 mg/kg dose
groups, respectively, and 3, 10, and 30 animals received
P188-NF in the 250, 500, and 1,000 mg/kg dose groups,
respectively. Serum samples for creatinine testing were
collected at 3 h (i.e., during the infusion), at 6 h (i.e., at the
end of the infusion) and at 24 and 48 h following the end of
the infusion (post-infusion). Creatinine levels were mea-
sured according to Heinega˚rd and Tiderstro¨m [35]. At 48 h
post-infusion, the animals were humanely euthanized and
their kidneys were harvested and processed for histopath-
ologic examination.
The reversibility of treatment-induced changes was
examined in a separate group of remnant-kidney rats fol-
lowing a 6-h infusion of either P188-P (1,000 mg/kg/h) or
P188-NF (1,000 mg/kg/h), with histopathology examina-
tion conducted at 24, 48, and 144 h post-infusion.
2.4 Histopathology
Tissue sections of the remnant kidneys were prepared
according to standard techniques and stained with hema-
toxylin and eosin (H&E) and with periodic acid–Schiff
(PAS). Light microscopic examinations were performed by
a renal pathologist blinded to treatment. Tissues were also
examined by transmission electron microscopy for treat-
ment-induced ultrastructural effects.
2.5 Clinical Studies
Two clinical studies were conducted to evaluate the effects
of P188-P on safety and renal function in patients with
SCD. Both studies involved test agent administration
consisting of a loading dose administered intravenously
over 1 h, followed by a maintenance dose administered
over either 23 or 47 h. In one study (study C97-1248), 126
subjects were treated with a total dose of 1.5 g/kg. In the
other study (study C97-1243), 42 subjects were random-
ized in an escalating manner to receive total doses ranging
from 1.1 to 2.9 g/kg. Urinary and plasma-based renal
function biomarkers were evaluated at baseline and
throughout the C97-1243 trial, and plasma creatinine was
assessed in both trials.
All studies were conducted according to Good Clinical
Practice (GCP)/International Conference on Harmonisation
(ICH) standards on consented subjects, and specimens
were collected accordingly.
3 Results
3.1 Purification of P188-NF
Representative GPC profiles of P188-NF and P188-P are
shown in Fig. 2. The predominant peak (between 14 and 15
minutes) identifies the desired molecular species. P188-NF
typically contains about 5 % (by weight) LMW substances
(\5,500 Da) [see Fig. 2a; dashed-line circle eluting after
15 min], which were targeted for removal. These LMW
substances are greatly reduced or absent in P188-P [see
Fig. 2b, dashed-line circle]. HMW contaminants (approx-
imately 16,000 Da) elute at between 13 and 14 min.
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3.2 Remnant-Kidney Animal Model
3.2.1 Histology and Ultrastructure
Histologic evaluation of H&E-stained sections of rem-
nant kidneys in rats infused with P188-NF demonstrated
dose-related diffuse cytoplasmic vacuolization in the
epithelial cells of the proximal convoluted tubule (PCT)
(Fig. 3). The vacuolization was restricted to the PCT, as
no changes were observed in the distal convoluted tubule
(DCT). The cytoplasmic vacuoles contained PAS-posi-
tive droplets, suggesting that they harbored reabsorbed
protein. PAS staining also revealed that the epithelial
brush borders were normal in appearance and the base-
ment membranes were intact. A similar pattern of dose-
related vacuolization was observed with P188-P,
although to a lesser extent. No other abnormalities related
to inflammation or necrosis were observed with either
treatment.
Electron microscopy revealed similar ultrastructural
findings to those seen with histologic evaluation. Rem-
nant kidneys treated with either P188-NF or P188-P
showed numerous cytoplasmic (apparently membrane-
bound) vacuoles containing electron-dense aggregates
(presumably protein). The vacuolization was again lim-
ited to the PCT, with none being detected in either the
DCT or the collecting ducts. There were no transition
forms to suggest that the vacuoles had been derived from
degenerating mitochondria. The epithelial brush borders
and basement membranes were intact and normal in
appearance, and there was no evidence of necrosis or
irreversible injury.
3.3 Effect on Creatinine
Treatment with P188-NF and P188-P resulted in dose-
dependent increases in serum creatinine at 24 h post-infu-
sion. However, the elevations in creatinine were generally
lower among animals treated with P188-P. At the highest
dose level (i.e., 1,000 mg/kg/h), the mean creatinine level
in animals treated with P188-NF at 24 h post-infusion was
2.48 mg/dL, representing an increase of 1.41 mg/dL from
baseline (Table 1). In comparison, the same parameter in
animals treated with P188-P was 1.73 mg/dL, representing
an increase of 0.86 mg/dL from baseline. Both the 24-h
creatinine levels and the changes in creatinine levels from
baseline to 24 h differed significantly between P188-P and
P188-NF (p = 0.0005 and p = 0.005, respectively).
Table 2 shows creatinine clearance values following
treatment with either P188-P or P188-NF. Creatinine
clearance was higher in animals treated with P188-P at
doses of 250 and 500 mg/kg/h than in animals treated with
P188-NF at similar doses. At 1,000 mg/kg/h, creatinine
clearance was high in both groups, with no difference
between treatments.
Survival following supra-pharmacologic dosing
(1,000 mg/kg/h) was higher at both 24 and 48 h post-
infusion in animals treated with P188-P than in those
treated with P188-NF (Fig. 4). Survival at 24 h was 92 %
(23/25) in animals treated with P188-P, compared with
64 % (16/25) in animals treated with P188-NF (p = 0.04).
Survival at 48 h was 70 % (21/30) and 50 % (15/30) for
P188-P and P188-NF, respectively (p = 0.3). Administra-
tion of equivalent amounts of the LMW substances isolated
















































Fig. 2 Gel permeation chromatography (GPC) profiles of a excipient-grade poloxamer 188 (P188-NF) and b purified poloxamer 188 (P188-P)
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in markedly reduced survival at 24 h (less than 10 %; data
not shown). Doses less than 1,000 mg/kg/h had negligible
effects on survival: only one of six rats died after infusion
with 500 mg/kg/h, and there was 100 % survival in the
250 mg/kg/h group.
The reversibility of the renal effects of P188-P and
P188-NF was also studied at 24, 48, 96, and 144 h post-
infusion following a dose of 1,000 mg/kg/h for 6 h. At
24 h, widespread vacuolization of PCT was observed with
both P188-P and P188-NF, with no major differences in the
degree of vacuolization between the two compounds.
However, by 48 h, widespread vacuolization was still
present with P188-NF, while much less vacuolization was
observed in animals infused with P188-P. At 96 h, minimal
vacuolization was observed with P188-P, while slightly
fewer but larger vacuoles were present in the P188-NF–
treated animals. At 144 h, vacuolization was no longer
observed and PCT appeared normal in P188-P–treated
animals, while some degree of vacuolization was still
observed in P188-NF–treated animals.
3.3.1 Clinical Studies
To date, there have been five clinical studies investigating
P188-P in healthy volunteers or in patients with SCD.
Various dosing regimens, involving both intravenous
loading and maintenance dosing, have been evaluated.
Fig. 3 Hematoxylin and eosin (H&E)-stained sections: the left panel
represents normal-appearing cells following a saline infusion; the
right panel represents the cytoplasmic vacuolization of the proximal
convoluted tubule (PCT), with sparring of the distal convoluted tubule
(DCT) observed more prominently with excipient-grade poloxamer
188 (P188-NF). Proximal convoluted tubules (P), distal tubules
(D) and glomeruli (G) are indicated (magnification, 9400)













250 1.07 ± 0.2 1.59 ± 0.7 ?0.52 ± 0.5
500 1.23 ± 0.3 1.85 ± 0.6 ?0.62 ± 0.5
1,000 1.07 ± 0.3 2.48 ± 0.6* ?1.41 ± 0.6**
P188-P
250 1.5 ± 0.5 2.15 ± 0.5 ?0.65 ± 0.7
500 0.93 ± 0.2 1.5 ± 0.2 ?0.57 ± 0.3
1,000 0.87 ± 0.3 1.73 ± 0.7* ?0.86 ± 0.7**
* p = 0.0005, ** p = 0.005 for the comparison between P188-NF
and P188-P
Table 2 Serum creatinine clearance in remnant-kidney animals




Creatinine clearance at end of infusion
(ll/min/100 g; mean ± standard deviation)
P188-NF
250 63 ± 40
500 86 ± 113
1,000 246 ± 141
P188-P
250 168 ± 116
500 164 ± 116
1,000 225 ± 217
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Study C97-1248 evaluated use of P188-P in SCD
patients with acute vaso-occlusive crisis (VOC). Two
hundred fifty-five (255) patients with SCD-VOC were
randomized to receive standard of care (hydration and
analgesics for pain) and either P188-P (test) or volume-
matched saline (control). The subjects had a serum creat-
inine level B1.0 mg/dL. Patients randomized to the test
arm received P188-P intravenously at a loading dose of
100 mg/kg over 1 h, followed by a maintenance dose of
30 mg/kg/h over 47 h, corresponding to a total dose of
1.5 g/kg. Patients randomized to the control arm received a
saline solution delivered at a volume and duration identical
to those used for the active drug. Serum was periodically
collected for creatinine testing both during the study and in
the follow-up period (i.e., [48 h). The mean serum creat-
inine level and standard deviation for all study subjects
over time are shown in Fig. 5. The mean values for serum
creatinine were not clinically or statistically different
between subjects treated with placebo and those treated
with P188-P, and neither group showed significant changes
from baseline through follow-up.
A summary table for serum creatinine elevations in
subjects enrolled in study C97-1248, stratified according to
toxicity grade, is shown in Table 3. The National Cancer
Institute Common Toxicity Criteria, Version 1, were used
in this analysis [36]. Any instances of elevated creatinine
values measured post-infusion were included in the table.
Overall, the incidence of elevated creatinine levels for all
grades was similar in both treatment groups.
Study C97-1243 was an open-label trial evaluating the
safety of varying doses of P188-P in pediatric and adult
SCD subjects experiencing acute chest syndrome. Five
different groups were intravenously administered a com-
mon loading dose of 200 mg/kg for 1 h, followed by
maintenance doses for 23 h. The maintenance dose was
different in each group and ranged from 20 to 120 mg/kg/h.
The total dose ranged from a low of 1.1 g/kg to a high of
2.9 g/kg. For comparison, the lower doses in study C97-
1243 overlapped with doses of P188-NF that yielded
unacceptable renal toxicity in AMI patients, while the
higher doses exceeded the maximum doses of P188-NF by
almost 2-fold. Study C97-1243 also included renal function
studies to assess the effect of P188-P on the nephron. These
assessments were performed on specimens collected at
baseline and upon completion of the P188-P infusion, as
well as on specimens collected 1 day, 2 days, 3 days,
5–10 days, and 28–35 days after the infusion. The tests that
were utilized, and the renal functions they evaluate (as
indicated in parentheses) are as follows: serum creatinine
(glomerular filtration), creatinine clearance (glomerular
filtration), b-N-acetylglucosaminidase levels (tubular
injury), retinol binding protein levels (protein absorption
pathways), albumin (integrity of glomerulus), immuno-
globulin G (IgG) excretion (glomerulus permeability), and
urine osmolarity (distal tubular transport).
Figure 6 presents the mean serum creatinine levels in
the dose groups in study C97-1243 during and after a 24-h
intravenous infusion of P188-P. The mean baseline creat-
inine levels were within normal ranges for all dose groups
(\136 lmol/L [\1.5 mg/dL] in men and \120 lmol/L
[\1.4 mg/dL] in women) [34]. Following treatment, the
mean values generally remained within the normal range
and there were no clear dose-related changes. In one group
(receiving 100 mg/kg/h), the data were skewed by a single
subject who developed septic shock with kidney failure,
which was determined by the investigator to be unrelated to
the treatment. Similarly, a transient rise in serum creatinine
on day 2 was observed in the 120 mg/kg/h group. This also
was unlikely to be indicative of a treatment-related effect,
since it was driven by a value from a single individual













24 hr 48 hr
P188-P
P188-NF
Fig. 4 Survival following supra-pharmacologic dosing of excipient-
grade poloxamer 188 (P188-NF) and purified poloxamer 188 (P188-
P) in remnant-kidney animals (n = 25 animals/group in each 24-h
group; n = 30 animals/group in each 48-h group). Survival
(%) = (number of animals alive at indicated time point/number of























Fig. 5 Changes in serum creatinine levels following administration
of purified poloxamer 188 (P188-P) or placebo to patients with sickle
cell disease (SCD). Each bar represents the mean ± standard
deviation for measurements conducted in the indicated group
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value actually represented a decrease from baseline.
Excluding these outliers, the data support that treatment
with P188-P does not result in differences in mean serum
creatinine across the dose range studied.
Figure 7 presents mean creatinine clearance values for
the dose groups in study C97-1243 during and after a 24-h
intravenous infusion of P188-P. Consistent with the serum
creatinine results, the serum creatinine clearance data does
not identify any dose-related changes or clinically signifi-
cant effects across time. A transient change in creatinine
clearance at day 2 was observed in the 120 mg/kg/h group;
however, this likely was influenced by the results from a
single subject, as previously noted.
Figures 8 and 9 present data obtained from tests per-
formed in study C97-1243 during and after a 24-h intrave-
nous infusion of P188-P in the dose groups that were studied.
Figure 8 presents results for urinary b-N-acetylglucosa-
minidase, and Fig. 9 presents results for retinol binding
protein levels. Collectively, these results and those from
testing urinary albumin, urinary IgE excretion, and urine
osmolarity (data not shown) did not reveal any dose-related
patterns or other changes suggestive of renal dysfunction
across the range of P188-P doses that were studied.
4 Discussion
We have prepared and studied a more homogeneous form
of P188 by removing certain LMW substances found in
commercially available, excipient-grade P188 and com-
paring the purified form (P188-P) with the unpurified
material (P188-NF). Since elevated creatinine was the
dose-limiting toxicity identified in prior clinical trials of
P188-NF, we compared the two materials using 5/6 neph-
rectomized rats, where 5/6 of kidney function is ablated
and the residual kidney is highly sensitive to the effects of
potential renal toxicants [32–34].
4.1 Renal Changes Following Exposure to P188 are
Consistent with Osmotic Nephrosis
Histologic evaluation of stained kidney sections from
nephrectomized rats infused with P188-P or P188-NF show
Table 3 Numbers of patients with elevated creatinine levels, stratified by toxicity grade and age, in study C97-1248
Toxicity gradea Subjects with elevated creatinine levels (n)
Adults (aged C16 years; n = 176) Children (aged \16 years; n = 73)
P188-P Placebo P188-P Placebo
1 46 49 18 14
2 12 9 5 3
3 1 0 0 1
4 0 0 0 0
P188-P purified poloxamer 188












































Fig. 6 Serum creatinine levels in patients treated with purified
poloxamer 188 (P188-P). Each bar represents the mean ± standard






























Fig. 7 Serum creatinine clearance in patients treated with purified
poloxamer 188 (P188-P). Each bar represents the mean ± standard
deviation for measurements conducted in the indicated group
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hydropic swelling and vacuolization within the epithelial
cells of the nephron’s PCTs. The effect is dose dependent,
with vacuolization restricted to the PCT. The presence of
PAS-positive droplets inside the cytoplasmic vacuoles
demonstrated that the vacuoles contained reabsorbed pro-
tein. However, even at the highest dose that was studied
(1,000 mg/kg/h), there was no histopathologic evidence of
tubule necrosis. Electron microscopy confirmed that the
brush border was anatomically intact and that the mito-
chondria appeared normal, showing no transition forms,
amplitude swelling, or formation of matrical granules.
Vacuolation of the renal tubule epithelium, like that
induced by P188, has been observed in Sprague–Dawley
rats during toxicologic evaluation of polyethylene glycol
(PEG)-linked proteins. Rather severe lesions were present
when lower molecular weight PEG-linked proteins were
tested, while minimal, if any, were seen with PEG-linked
proteins [70 kD, suggesting that protein with attached
PEG was reabsorbed by the proximal tubules. The
observed vacuolation that accompanied the response was
thought to result from fluid distension within lysosomes
due to the hygroscopic nature of PEG [37]. Unconjugated
PEG, of masses similar to that of P188, preferentially
accumulate in the renal epithelium [38]. Others have dis-
cussed that lysosomal dysfunction, presenting as intracel-
lular vacuolation, is a common feature of biopersistent
materials, such as PEG [39].
The hydropic swelling and vacuolization induced by P188
also resembles a type of vacuolar nephrosis deemed osmotic
or hypokalemic nephrosis. It is considered a reversible
condition, often observed in patients after infusion with
hypertonic solutions of sucrose, mannitol, or dextran. In a
recent clinical study, infusion of immunoglobulin prepara-
tions containing sucrose as a stabilizing agent resulted in a
fully reversible form of acute renal failure, with histologic
changes characterized by vacuolization and swelling of renal
proximal tubule cells. The authors suggested that the risk of
such injury could be minimized by dilution of the immuno-
globulin preparation and by slowing the infusion rate [40].
Hypokalemic nephrosis, a condition commonly seen in cases
of chronic diarrhea, is due to potassium depletion. This
condition, which is caused by disturbance in the osmotic and
electrolyte balance within the tubule cells, also is fully
reversible.
4.2 P188-P is Less Injurious, and Changes are More
Readily Reversible
Both P188-NF and P188-P induced dose-dependent
increases in serum creatinine levels. However, at high
doses, the elevation in serum creatinine levels induced by
P188-NF was significantly greater than what was observed
with P188-P. Mortality at 24 h was significantly higher in
animals administered P188-NF than in animals receiving
P188-P (30.77 versus 11.48 %; p \ 0.01). Mortality at
48 h was also reduced with P188-P, though the difference
was not statistically significant.
It is important to point out that, when administered to
rats with intact renal function at the dosages used in this
study, P188-NF is well tolerated and changes in creatinine
are not observed. This suggests that the mortality observed
in the 5/6-remnant rats is due to their increased sensitivity
to renal toxicants resulting from loss of renal function.
Likewise, the improved survival with P188-P suggests that
purified P188 is likely to be better tolerated when renal
function is compromised.
We also examined the reversibility of vacuolar lesions
following infusion of P188-P or P188-NF in the nephrec-
tomized rat. Infusion with P188-P at supra-pharmacologic
dosing produced coarse vacuolization, which had com-
pletely reversed by 96–144 h after infusion. In contrast, the
vacuolization produced by P188-NF involved a slower rate
of recovery, since coarse vacuolization was still present
144 h following infusion.
We conclude from these observations in nephrectomized

























Fig. 8 Urinary b-N-acetylglucosaminidase (NAG) levels in patients
treated with purified poloxamer 188 (P188-P). Each bar represents the























Fig. 9 Retinol binding protein levels in patients treated with purified
poloxamer 188 (P188-P). Each bar represents the mean ± standard
deviation for measurements conducted in the indicated group
80 M. Emanuele, B. Balasubramaniam
P188-NF is markedly attenuated with P188-P, suggesting
that LMW substances present in P188-NF contribute sub-
stantially to its effect on renal function. Further, the
changes do not involve inflammation or necrosis, resemble
osmotic nephrosis, and are fully reversible. It most likely
represents an exaggeration of the normal vacuolar reab-
sorption pathway.
4.3 The Renal Dysfunction Observed in Clinical
Studies of P188-NF is not Observed in Clinical
Studies of P188-P
Following discussions with the US Food and Drug
Administration regarding the remnant-kidney animal
model and the results of clinical studies in healthy volun-
teers, study C97-1248 was initiated. Patient serum creati-
nine levels were monitored for 28 days after a 48-h
infusion with P188-P or placebo. At all evaluation time
points, there was no difference in mean serum creatinine
levels between treatment arms. Changes in serum creati-
nine were also graded according to the National Cancer
Institute Common Toxicity Criteria. Overall, the incidence
of elevated creatinine for all grades was similar in both
treatment groups. Importantly, there was a single instance
of grade 3 creatinine elevation in each treatment arm and
no instances of grade 4 changes.
Study C97-1243 evaluated the safety of administering
increasing doses of P188-P to pediatric and adult SCD
patients experiencing acute chest syndrome. Subjects were
administered a 1-h loading dose followed by a maintenance
dose, which was administered over 23 h. The total dose of
P188-P that was administered ranged from a low of 1.1 g/
kg to a high of 2.9 g/kg. Across all dose groups, there were
no clinically or statistically significant differences in mean
serum creatinine levels or mean creatinine clearance from
baseline or between groups. Similarly, no changes from
baseline or between dose groups was observed in a variety
of renal function tests, including urinary b-N-acetylgluco-
saminidase, urinary retinol binding protein, urine albumin
levels, IgG excretion, and urine osmolarity.
It is worthwhile to compare the renal toxicity observed
in patients receiving P188-NF with the renal toxicity
observed in patients receiving P188-P. In AMI patients,
P188-NF resulted in measurable dose-dependent increases
in serum creatinine across a dose range from about 300 to
about 1,800 mg/kg. In the higher-dose groups, the mean
change from baseline was between 0.5 and 0.6 mg/dL. In
contrast, in SCD patients, P188-P resulted in no dose-
dependent changes in mean creatinine or changes from
baseline at significantly higher doses (between 1.1 and
2.9 g/kg). While the two study populations are not directly
comparable, in light of the benefits associated with P188-P
in nonclinical studies, it is reasonable to conclude that the
improved renal outcomes observed with P188-P are
derived from the selective removal of LMW substances
present in P188-NF.
Finally, it is worth commenting on the role of the LMW
substances in mediating adverse renal effects. It has been
reported by Schmolka and others that the toxicity of pol-
oxamers increases with decreasing molecular weight and
an increasing hydrophobic/hydrophilic ratio [41]. This is
because as poloxamers become smaller and more hydro-
phobic, they likely behave more like detergents, such as
Triton X-100, which are known to be injurious to cells
through disruption of cell membranes. In contrast, larger,
more relatively hydrophilic poloxamer molecules, such as
the species contained in the main peak of poloxamer 188,
have the opposite effect and act as membrane sealants [42].
Accordingly, we believe that certain LMW components of
the poloxamer 188 polymeric distribution may act more
like Triton detergents to initiate or propagate membrane
injury and, through this mechanism, may contribute to
adverse renal effects.
5 Conclusions
1. The renal dysfunction associated with P188-NF
(commercially available, excipient-grade material) is
dose dependent and is characterized histologically by
coarse vacuolization in the proximal tubule epithelium,
with no evidence of necrosis or irreversible cellular
damage.
2. The renal dysfunction observed with P188-NF is
associated with LMW substances present in P188-
NF. These substances can be reduced via supercritical
fluid extraction.
3. Compared with P188-NF, P188-P with reduced LMW
substances was better tolerated in a remnant-kidney
animal model. In this model, P188-P resulted in less
pronounced vacuolization, with more rapid recovery,
less effect on serum creatinine, and significantly
improved tolerability. Any effects of P188-P on renal
function are predicted to be fully reversible.
4. In studies investigating P188-P, the pattern of dose-
dependent changes in serum creatinine previously
observed with P188-NF was not observed, even with
significantly higher levels of exposure. This suggests
that the benefits of P188-P observed in animal studies
translate to humans.
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